The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors
- 14 August 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (9) , 3090-3100
Abstract
Despite advances in anticoagulant drug discovery to establish a new standard of care, represented by Factor Xa (FXa) inhibitors, additional therapies are needed to address the concomitant bleeding risk posed by these agents. Factor XI (FXI) plays a key role in the intrinsic coagulation cascade contributing to thrombin generation and fibril formation, and there is an increasing weight of evidence supporting a comparable efficacy and superior safety profile of FXI-based oral anticoagulants. A novel allosteric mechanism of action (MoA) for inhibiting FXI activation to Factor XIa (FXIa) was discovered by applying an AS-MS-based screen to the FXI zymogen. Biochemical and biophysical characterization of these structurally diverse small-molecule classes confirmed this mode of inhibition as specific to the FXI zymogen, and a high-resolution FXI-inhibitor cocomplex structure identified the binding pocket that is distal to the FXI cleavage site. These FXI Activation Inhibitors were active in translational functional assays, prolonging activated partial thromboplastin time (aPTT) in human plasma and demonstrating dose-dependent antithrombotic effects in the rabbit arteriovenous-shunt model of thrombosis. The results affirm that FXI Activation Inhibitors are a novel mechanism for the potential treatment of thrombotic disorders.Keywords
This publication has 47 references indexed in Scilit:
- Intrinsic Pathway of Coagulation and Arterial ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- The intrinsic pathway of coagulation: a target for treating thromboembolic disease?Journal of Thrombosis and Haemostasis, 2007
- Crystal structure of the factor XI zymogen reveals a pathway for transactivationNature Structural & Molecular Biology, 2006
- Cardiovascular DiseaseNew England Journal of Medicine, 2003
- Thrombosis in Ischemic Heart DiseaseArchives of internal medicine (1960), 1996
- Antithrombotic Activity of Argatroban in Experimental Thrombosis in the RabbitSeminars in Thrombosis and Hemostasis, 1996
- Factor XI Deficiency in Ashkenazi Jews in IsraelNew England Journal of Medicine, 1991
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991
- EFFECT OF ANTIHEMOPHILIC FACTOR ON ONE-STAGE CLOTTING TESTS - A PRESUMPTIVE TEST FOR HEMOPHILIA AND A SIMPLE ONE-STAGE ANTIHEMOPHILIC FACTOR ASSAY PROCEDURE1953
- The Control of Dicumarol Therapy and the Quantitative Determination of Prothrombin and ProconvertinScandinavian Journal of Clinical and Laboratory Investigation, 1951